Method for cancer immunotherapy

1. A method for treating cancer, the method comprising:

administering to a subject in need thereof who is positive for HLA-A24 and positive for WT1 protein a therapeutically effective amount of a compound of formula (1) or a pharmaceutically acceptable salt thereof;

wherein formula (1) is:

wherein X is a tyrosine residue or a methionine residue; each of Y and Z is independently selected from the group consisting of a single bond and a divalent peptide group consisting of 1-10 amino acid residues,

R 1 is hydrogen or alkyl,

R 2 is hydroxyl, amino, alkylamino or dialkylamino,

R 3 is hydrogen, alkyl, amino, alkylamino, dialkylamino or substituted or unsubstituted alkylcarbonylamino,

R 4 is hydrogen, alkyl, carboxy, carbamoyl, alkylcarbamoyl, dialkylcarbamoyl or a group of formula (2):

wherein:

W is an amino acid residue,

m is 1 or 2, and

n is an integer of 0-2,

with the proviso that when n is 0, then R 3 is hydrogen or alkyl.

2. The method of claim 1 that comprises administering a compound of formula (1) or a pharmaceutically acceptable salt thereof, wherein R 1 is hydrogen.

3. The method of claim 1 that comprises administering a compound of formula (1) or a pharmaceutically acceptable salt thereof, wherein R 3 is amino, alkylcarbonylamino or substituted alkylcarbonylamino.

4. The method of claim 1 that comprises administering a compound of formula (1) or a pharmaceutically acceptable salt thereof

wherein the compound is:

5. The method of claim 1 that comprises administering a compound of formula (1) or a pharmaceutically acceptable salt thereof wherein the compound is:

6. The method of claim 1 , wherein cancer cells of the subject express WT1 protein.